- Home
- ALLY vs MRNA Comparison
ALLY vs MRNA Comparison
Compare ALLY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLY
- MRNA
- Stock Information
- Founded
- ALLY 1919
- MRNA 2010
- Country
- ALLY United States
- MRNA United States
- Employees
- ALLY N/A
- MRNA N/A
- Industry
- ALLY Major Banks
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLY Finance
- MRNA Health Care
- Exchange
- ALLY Nasdaq
- MRNA Nasdaq
- Market Cap
- ALLY 9.2B
- MRNA 10.6B
- IPO Year
- ALLY 2014
- MRNA 2018
- Fundamental
- Price
- ALLY $34.99
- MRNA $26.56
- Analyst Decision
- ALLY Buy
- MRNA Hold
- Analyst Count
- ALLY 19
- MRNA 19
- Target Price
- ALLY $43.00
- MRNA $48.13
- AVG Volume (30 Days)
- ALLY 4.0M
- MRNA 14.2M
- Earning Date
- ALLY 07-16-2025
- MRNA 05-01-2025
- Dividend Yield
- ALLY 3.43%
- MRNA N/A
- EPS Growth
- ALLY N/A
- MRNA N/A
- EPS
- ALLY 0.61
- MRNA N/A
- Revenue
- ALLY $6,658,000,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- ALLY $20.04
- MRNA N/A
- Revenue Next Year
- ALLY $14.93
- MRNA $8.98
- P/E Ratio
- ALLY $56.93
- MRNA N/A
- Revenue Growth
- ALLY N/A
- MRNA N/A
- 52 Week Low
- ALLY $29.52
- MRNA $23.15
- 52 Week High
- ALLY $45.46
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- ALLY 53.65
- MRNA 50.60
- Support Level
- ALLY $32.50
- MRNA $25.22
- Resistance Level
- ALLY $37.19
- MRNA $27.15
- Average True Range (ATR)
- ALLY 0.85
- MRNA 1.61
- MACD
- ALLY -0.02
- MRNA 0.26
- Stochastic Oscillator
- ALLY 53.07
- MRNA 47.66
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.